MPR Weekly Dose Podcast

This week: FDA votes on possible peanut allergy treatment; New risks ID’d with some breast cancer drugs; A topical solution for common warts; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality.

This week: Pimavanserin trial stopped early; Influenza vaccination updates; The unusual case of the label update that wasn’t; E-cigarettes and lung illness; and new proposals from the DEA to reduce opioid production but to increase marijuana production.

This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; and Fast track designation for a kidney disease therapy and for a degenerative disc disease therapy.

This week: New draft guidelines for Lyme Disease management; First-in-class antibiotic to treat community-acquired bacterial pneumonia; Duchenne muscular dystrophy drug denied; Approval for a rheumatoid arthritis treatment; and the FDA make a decision on Hetlioz for jet lag disorder.

This week: Dangerous products being sold as “cure alls,” results of a safety review for a Parkinson disease treatment, a new drug for hard-to-treat TB, differences in prescription use between the US and Canada, and a unique test for chlamydia and gonorrhea.